Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer …
Biotechnology
US, Seattle [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Adaptive Biotechnologies Corporation's gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | - | -1.007 | - | 82 | - | -145 | - | -80 | - | -82 | - | 83 |
| 2020 | -0.8500 | -1.079 | 85 | 95 | -58 | -135 | -70 | -128 | -78 | -142 | 68 | 95 |
| 2021 | -1.0600 | -1.492 | 98 | 152 | -139 | -232 | -144 | -216 | -152 | -234 | 110 | 154 |
| 2022 | -1.4600 | -1.471 | 154 | 185 | -205 | -258 | -193 | -237 | -208 | -259 | 169 | 186 |
| 2023 | -1.0000 | -1.413 | 185 | 172 | -142 | -225 | -167 | -260 | -200 | -285 | 184 | 174 |
| 2024 | -1.5600 | -1.115 | 170 | 177 | -225 | -160 | -189 | -168 | -227 | -174 | 172 | 179 |
| 2025 | - | -0.938 | - | 211 | - | -140 | - | -200 | - | -207 | - | 213 |
| 2026 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |